TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10963018
Drug: ART therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART therapy
Study: 10963018
Drug: MET therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MET therapy
Study: 8855091
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 600 mg/day for 20 days
Study: 6091476
Drug: Ceftriaxone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (1 g preoperative dose, placebo at 8 and 16 hours later)
Study: 31370809
Drug: 1 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg paricalcitol
Study: 31370809
Drug: 2 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 μg paricalcitol
Study: 26325514
Drug: Dexmedetomidine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.2 to 0.7 μg/kg/h)
Study: 26325514
Drug: Remifentanil (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (0.08 to 0.15 μg/kg/min)
Study: 18056490
Drug: Standard pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pain management alone (typically intravenous narcotics)
Study: 15749490
Drug: Sperm treatment
Normalized name: herring sperm DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sperm treatment with exogenous PAF (10(‐7) mol/L) in sperm-washing medium, direct swim-up technique, maximum of six IUI cycles
Study: 15749490
Drug: Direct swim-up
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct swim-up technique without PAF treatment
Study: 9094145
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day selegiline
Study: 9094145
Drug: 60 mg/day
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/day selegiline
Study: 1553901
Drug: Indicine N-oxide
Normalized name: Pyridinethiol N-oxide
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indicine N-oxide at 2,000 mg/m2/day for 5 consecutive days
Study: 1553901
Drug: Indicine N-oxide
Normalized name: Pyridinethiol N-oxide
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indicine N-oxide at 2,500 mg/m2/day for 5 consecutive days
Study: 3964332
Drug: Preparation B
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation B (soft gelatine capsule with liquid nifedipine)
Study: 22996849
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural injections with 0.5% lidocaine mixed with 1 mL of steroid (6 mg non-particulate betamethasone)
Study: 12209526
Drug: Celecoxib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (100 mg, 200 mg)
Study: 7747322
Drug: Diethylcarbamazine (DEC,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylcarbamazine (DEC, 6 mg/kg)
Study: 2153393
Drug: Chemotherapy (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (cyclophosphamide 1 g m‐2 i.v. day 1, vincristine 2 mg i.v. day 1, etoposide 100 mg tds p.o. days 1‐3, repeated every 21 days)
Study: 28098515
Drug: Ezetimibe (EZ)
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe (EZ) 10 mg/day
Study: 28098515
Drug: Plant Sterol
Normalized name: plant sterol complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant Sterol (PS) 2 g/day
Study: 28098515
Drug: Ezetimibe +
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe + Plant Sterol (EZ+PS) 10 mg/day + 2 g/day
Study: 28098515
Drug: Control (CT)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (CT) group on same statin therapy
Study: 19185647
Drug: Clopidogrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel plus aspirin for 1 year
Study: 19185647
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus aspirin for 1 year
Study: 9590187
Drug: ABLC (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABLC (5 mg/kg/d)
Study: 9590187
Drug: AmB (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmB (0.6 to 1 mg/kg)
Study: 3049485
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of naproxen sodium
Study: 3049485
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of naproxen sodium
Study: 19001024
Drug: Chlorthalidone/amlodipine/lisinopril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone/amlodipine/lisinopril
Study: 1629380
Drug: Trazodone, mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone, mean daily dose 235 +/- 10 mg, 10 weeks
Study: 1629380
Drug: Clomipramine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine and fluoxetine
Study: 6380301
Drug: Low calcium
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calcium diet (300 mg calcium/day)
Study: 6380301
Drug: Low calcium
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calcium diet plus hydrochlorthiazide (25 mg twice a day)
Study: 18388340
Drug: sarpogrelate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: sarpogrelate (100 mg TID)
Study: 18388340
Drug: aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin (81 mg/d)
Study: 8679834
Drug: Parenteral S-adenosylmethionine
Normalized name: S-adenosylmethionine
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral S-adenosylmethionine (SAMe)
Study: 1726758
Drug: Palliative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative treatment only
Study: 1726758
Drug: Palliative and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative and isoprinosine treatment
Study: 1726758
Drug: Palliative and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative and acyclovir treatment
Study: 1726758
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (palliative, isoprinosine, and acyclovir)
Study: 6219903
Drug: Combination tablet
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination tablet containing orphenadrine citrate and paracetamol ('Norgesic')
Study: 28353116
Drug: 40-unit RCI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-unit RCI twice a week
Study: 28353116
Drug: 80-unit RCI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80-unit RCI twice a week
Study: 18080763
Drug: IFN beta‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN beta‐1a plus RBV (1,000‐1,200 mg/day)
Study: 11306831
Drug: Topical tacalcitol
Normalized name: tacalcitol Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tacalcitol
Study: 9209899
Drug: Nafarelin 200
Normalized name: nafarelin 200 MCG/ACTUAT Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin 200 micrograms plus Norethisterone 1.2 mg (Group C)
Study: 8132186
Drug: Clozapine treatment
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine treatment for one year
Study: 3191000
Drug: Topical minoxidil
Normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical minoxidil
Study: 30597503
Drug: Adjusted dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted dose of enoxaparin according to anti-factor Xa levels
Study: 21142609
Drug: 300 μg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 μg/day transdermal testosterone patch (TTP)
Study: 14723338
Drug: Blend of
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blend of partially purified Yucca schidigera and Quillaja saponaria extracts (0.9 mg daily for 4 weeks)
Study: 8732309
Drug: 600-1200 mg
Normalized name: pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 600-1200 mg of CX516
Study: 25864194
Drug: Single-dose trandolapril
Normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose trandolapril (1 mg, 2 mg, 4 mg)
Study: 25864194
Drug: Multiple-dose trandolapril
Normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple-dose trandolapril (2 mg/day for 6 days)
Study: 25864194
Drug: Single-dose trandolapril
Normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose trandolapril
Study: 25864194
Drug: Single and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single and multiple doses of trandolapril
Study: 18333870
Drug: Maraviroc (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maraviroc (doses ranged from 3 mg b.i.d. to 600 mg q.d.)
Study: 14575630
Drug: Southern Implant
Normalized name: Fluzone 2025 Southern Hemisphere
Approvals — FDA: no, EMA: no, PMDA: no
Description: Southern Implant System
Study: 9493701
Drug: Barnidipine 10
Normalized name: barnidipine
DrugBank: Barnidipine (DB09227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barnidipine 10 mg
Study: 11221289
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with enalapril (up to 10 mg once daily)
Study: 1557929
Drug: 1.0 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 micrograms antigen per dose, abbreviated schedule (days 0, 7, 21)
Study: 1557929
Drug: 1.0 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 micrograms antigen per dose, conventional schedule (days 0, 28, 300)
Study: 1557929
Drug: 1.5 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 micrograms antigen per dose, conventional schedule (days 0, 28, 300)
Study: 1557929
Drug: 2.0 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 micrograms antigen per dose, conventional schedule (days 0, 28, 300)
Study: 1557929
Drug: 1.5 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 micrograms antigen per dose, abbreviated schedule (days 0, 7, 21)
Study: 1557929
Drug: 2.0 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 micrograms antigen per dose, abbreviated schedule (days 0, 7, 21)
Study: 4093346
Drug: Piperacillin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin (4 X 2 g for 48 h)
Study: 19695387
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg (followed by 200 mg q12h)
Study: 19695387
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium 550 mg (followed by 550 mg q12h)
Study: 19695387
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium 550 mg (study 2 only)
Study: 16544756
Drug: Homeopathic drug
Normalized name: homeopathic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic drug 'Avia-more'
Study: 14557430
Drug: Oral weekly
Normalized name: ELAGOLIX/ESTRADIOL/NORETHINDRONE CAP,ORAL WEEKLY PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral weekly ibandronate (20 mg)
Study: 14557430
Drug: Both regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both regimens (weekly and daily ibandronate)
Study: 9088782
Drug: Subcutaneous nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous nicotine injections (2 x 0.3 mg)
Study: 9088782
Drug: Subcutaneous nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous nicotine injections (2 x 0.6 mg)
Study: 9088782
Drug: Subcutaneous nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous nicotine (0.6 mg)
Study: 1490435
Drug: Aztreonam, intramuscularly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam, intramuscularly at a level of 50 to 80 mg/kg body weight per dose every 8 h for 7 days
Study: 1490435
Drug: Chloramphenicol, orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramphenicol, orally in a dose of 50 to 70 mg/kg body weight every 6 h for 12 days
Study: 29943838
Drug: Antifungal agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifungal agents (systemic and topical)
Study: 28831618
Drug: Behavioral HIV
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral HIV prevention intervention integrating in-person and mobile phone delivered HIV risk reduction counseling, and daily, personalized text or voice messages.
Study: 18838938
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (including saline)
Study: 18838938
Drug: Inhaled bronchodilator
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled bronchodilator treatments
Study: 3777409
Drug: Nalbuphine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 2.5 mg
Study: 12618286
Drug: Nalbuphine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 2.5 mg + Naloxone 0.4 mg
Study: 3777409
Drug: Nalbuphine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 5 mg
Study: 15834273
Drug: Caffeine (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (median dose: 410 mg/day)
Study: 15834273
Drug: Coffee (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee (median intake: 725 ml/day)
Study: 7721409
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 mg on each of 5 days preceding the study)
Study: 7721409
Drug: Candoxatrilat (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candoxatrilat (200 mg IV)
Study: 6786952
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (nutrient solution of hypertonic glucose and amino acids, 44.7 +/- 9.0 kcal/kg/day)
Study: 31833718
Drug: 5-alpha reductase
Normalized name: 5-alpha reductase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-alpha reductase inhibitors (5-ARIs) for at least 12 months
Study: 31833718
Drug: Untreated with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Untreated with 5-alpha reductase inhibitors (5-ARIs)
Study: 18762438
Drug: Prolonged-release oral
Normalized name: Niacin 1 g prolonged-release oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release oral oxycodone co-administered with naloxone (10 mg/day, 20 mg/day, 40 mg/day)
Study: 18762438
Drug: Prolonged-release oral
Normalized name: Niacin 1 g prolonged-release oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release oral naloxone (20 mg/day and 40 mg/day)
Study: 17525906
Drug: 1-hour infusion
Normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour infusion of daunorubicin (DNR) at a dose of 36 mg/m²
Study: 17525906
Drug: 24-hour infusion
Normalized name: respiratory syncytial virus pre-fusion F protein, recombinant 0.24 MG/ML [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour infusion of daunorubicin (DNR) at a dose of 36 mg/m²
Study: 17525906
Drug: 1-hour infusion
Normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour infusion of daunorubicin (DNR)
Study: 17525906
Drug: 24-hour infusion
Normalized name: respiratory syncytial virus pre-fusion F protein, recombinant 0.24 MG/ML [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour infusion of daunorubicin (DNR)
Study: 2866607
Drug: Acetylcysteine 200
Normalized name: acetylcysteine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcysteine 200 mg three times a day
Study: 15107600
Drug: Levosimendan (LS)
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (LS) 0.5 mg four times daily with felodipine (FD) 5 mg once daily
Study: 15107600
Drug: Felodipine (FD)
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine (FD) 5 mg once daily
Study: 8838439
Drug: Ethanol (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.15 g kg-1)
Study: 1595589
Drug: Chronic magnesium
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic magnesium administration (CMA) 4.5 g/d for 4 weeks
Study: 31477748
Drug: Preservative-free diquafosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free diquafosol administered 6 times daily after surgery
Study: 31477748
Drug: Preservative-containing diquafosol
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-containing diquafosol administered 6 times daily after surgery
Study: 31477748
Drug: Preservative-free hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free hyaluronate administered 6 times daily after surgery
Study: 29504880
Drug: Acetaminophen/Codeine (Tylex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen/Codeine (Tylex 30 mg: acetaminophen 500 mg/codeine 30 mg)
Study: 29504880
Drug: Acetaminophen/Codeine (Tylex)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen/Codeine (Tylex)
Study: 22471392
Drug: Perindopril 4
Normalized name: perindopril 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 4 mg for 4 weeks
Study: 21883698
Drug: Capsaicin (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin (0.75 mg)
Study: 9011455
Drug: Somatostatin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (250 microg bolus injection)
Study: 3904436
Drug: Buffered aspirin
Normalized name: Buffered Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buffered aspirin
Study: 25706772
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa (NS) 2g daily for one year
Study: 20026488
Drug: Hyaluronan-based heparin-bonded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronan-based heparin-bonded circuits (Vision HFO-GBS, Gish, CA, USA)
Study: 10435208
Drug: Naloxone 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 2.0 mg/kg
Study: 8627976
Drug: Intracoronary nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary nicorandil (0.25, 0.50, 1.0 mg)
Study: 8627976
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN; 1.0 mg)
Study: 6793182
Drug: Chlorpropamide (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpropamide (two weeks treatment)
Study: 6793182
Drug: Chlorpropamide (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpropamide (single tablet)
Study: 19811373
Drug: Augmentation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation therapy with exogenous α1-antitrypsin (α1-AT)
Study: 2806927
Drug: control experiments
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL GEL [Quality Metalcraft Experi-Metal Alcohol Antiseptic 80% Topical Solution Hand Sanitizer Non-sterile Solution]
Approvals — FDA: no, EMA: no, PMDA: no
Description: control experiments without levodopa administration
Study: 335382
Drug: Nerisone cream
Normalized name: Nerisone
DrugBank: Difluocortolone (DB09095)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerisone cream (diflucortolone valerate 0.1%)
Study: 335382
Drug: Fluocinolone-acetonide ointments
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone-acetonide ointments
Study: 23867047
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual drug education)
Study: 17485709
Drug: Peritumoral injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritumoral injection of blue dye
Study: 17485709
Drug: Peritumoral injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritumoral injection by probe
Study: 17485709
Drug: Periareolar injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periareolar injection
Study: 17485709
Drug: Peritumoral injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritumoral injection
Study: 7985162
Drug: Capoten treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capoten treatment according to the chronosensitivity-adjusted regimen
Study: 9620514
Drug: Alfentanil 0.5
Normalized name: alfentanil 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 0.5 mg
Study: 30911271
Drug: Single-dose dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose dexmedetomidine (0.5 μg/kg) combined with low-dose remifentanil infusion (1 ng/mL)
Study: 30911271
Drug: High-dose remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose remifentanil infusion (2 ng/mL)
Study: 21178605
Drug: Preemptive low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preemptive low-dose epidural ketamine (0.12% levobupivacaine, 2 μg/mL of fentanyl, 0.2 mg/mL ketamine, total volume of 500 mL)
Study: 18155054
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (lidocaine 2.5% and prilocaine 2.5%), approximately 5 g
Study: 18155054
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (neomycin ointment, approximately 5 g)
Study: 22516310
Drug: Celecoxib (200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200mg twice daily)
Study: 11137591
Drug: Antibiotics prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics prescribed at discharge (amoxicillin clavulanate in 41%, amoxicillin in 15%, cefuroxime axetil in 11%, cefaclor 6%, azithromycin 5%)
Study: 11137591
Drug: First choice
Normalized name: First Choice Strip
Approvals — FDA: no, EMA: no, PMDA: no
Description: First choice antibiotics
Study: 11137591
Drug: Alternate use
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate use antibiotics